Forte Biosciences (FBRX) Cash from Financing Activities (2016 - 2026)
Forte Biosciences (FBRX) reported Cash from Financing Activities of $74000.0 for Q1 2026, up 103.19% year-over-year from $36419.7 in Q1 2025, and up 722.22% quarter-over-quarter from $9000.0 in Q4 2025.
Forte Biosciences (FBRX) Cash from Financing Activities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Cash from Financing Activities data on file, last reported at $74000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $74000.0, up 103.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.8 million (up 44.84% YoY), and the FY2025 annual result was $69.4 million, up 33.75% from the prior year.
- Cash from Financing Activities advanced to $74000.0 in Q1 2026 per FBRX's latest filing, from $9000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $70.3 million in Q2 2025 and troughed at -$2.3 million in Q1 2025.
- A 5-year average of $9.0 million and a median of -$2000.0 in 2024 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 703590.0% in 2025 and fell as far as 28925.0% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$55000.0 in 2022, then plunged by 36.36% to -$75000.0 in 2023, then jumped by 69269.33% to $51.9 million in 2024, then plunged by 99.98% to $9000.0 in 2025, then jumped by 722.22% to $74000.0 in 2026.
- Business Quant data shows FBRX's Cash from Financing Activities at $74000.0 in Q1 2026, $9000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | 74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 70.35 Mn |
| Jun 30, 2025 | 70.35 Mn |
| Mar 31, 2025 | -2.32 Mn |
| Mar 31, 2025 | -2.32 Mn |
| Dec 31, 2024 | 51.88 Mn |
| Dec 31, 2024 | 51.88 Mn |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | -75,000.00 |
| Dec 31, 2023 | -75,000.00 |